274 results match your criteria: "Centre de Transfusion Sanguine[Affiliation]"
Clin Dermatol
June 1993
Centre de Transfusion Sanguine, Hospital Cantonal Universitaire, Geneva, Switzerland.
Br J Haematol
August 1992
Centre de Transfusion Sanguine, Centre Hospitalier Universitaire, Grenoble, France.
The lipid-binding inhibitor of coagulation, beta 2-glycoprotein I (beta 2GPI), has been shown to form the antigen to which some autoantibodies against anionic phospholipids (aPL) are directed. Six murine monoclonal antibodies (MAbs) of the IgG1 isotype were raised against human beta 2GPI and could be subdivided into three groups on the basis of mutual competition experiments. MAbs 9G1 and 8C3 (group A) markedly inhibited the binding of immunoglobulins from aPL-positive sera to beta 2GPI-coated wells.
View Article and Find Full Text PDFHigh-resolution two-dimensional gel electrophoresis (2-DGE) was used to analyse plasma samples and partially purified cold agglutinins (CA) obtained from two selected patients. Both presented an acute hemolytic anemia with CA of high thermal amplitude, normal immunoglobulin levels, no detectable paraproteinemia, and no clinical evidence of a malignant B-cell disorder. The electrophoretograms of their plasma showed evident alternations of the "normal" protein profile, which were directly related to hemolysis (absence of the spots of haptoglobin and in one case of those of hemopexin), but no monoclonal gammopathy.
View Article and Find Full Text PDFTransfus Sci
July 1992
Centre de Transfusion Sanguine, Croix-Rouge suisse, Lausanne, Switzerland.
Thromb Haemost
May 1992
Laboratoire d'Hémostase, Centre de Transfusion Sanguine, Toulouse, France.
This paper reports on the pharmacodynamic properties of butyryl derivatives of unfractionated heparin (C4-UH) and of low molecular weight heparin (C4-CY 216) after bolus intravenous injection, constant infusion and subcutaneous administration to rabbits. The pharmacodynamic properties of the two butyryl derivatives were compared to those of the parent compounds, unfractionated heparin (UH) and low molecular weight heparin (CY 216). After bolus intravenous injection of increasing doses, the disposition of the butyryl derivatives were comparable to that of their parent compounds up to 3 mg kg-1.
View Article and Find Full Text PDFBr J Haematol
May 1992
Service de Cryobiologie, Centre de Transfusion Sanguine, Lyon, France.
Surface markers were studied at first relapse in 66 cases of acute myeloid leukaemia (AML), using a panel of five monoclonal antibodies directed to CD13, CD14, CD15, CD33 and CD34 antigens. At time of relapse, there was increased expression of CD33 (P = 0.002) and CD34 (P = 0.
View Article and Find Full Text PDFPrior studies have shown that multidrug resistance gene products may be detected in acute myeloid leukemia (AML) cells, and are associated with poor response to therapy. We studied whether P-170 expression was associated with in vitro daunorubicin (DNR) accumulation and sensitivity of leukemic clonogenic cells (CFU-L) to DNR in 16 newly diagnosed AML samples. P-170 expression was assessed by indirect immunofluorescence using the monoclonal antibody MRK16.
View Article and Find Full Text PDFA process to subject pooled human plasma to a viral inactivation treatment by heating in the liquid state for 10 hrs at 60 degrees C (pasteurization) has been designed and evaluated. Activity recovered from clotting factors and protease inhibitors exceeded 80%. Overall clotting activity remained good.
View Article and Find Full Text PDFThromb Haemost
March 1992
Laboratoire d'Hémostase, Centre de Transfusion Sanguine, Toulouse, France.
We have investigated the pharmacological properties of an O-acetylated butyryl derivative of the low molecular weight heparin CY 216 (C4-CY 216). In a purified system the ability of C4-CY 216 to catalyze thrombin and factor Xa inhibition was comparable to that of CY 216. The antithrombin and antifactor Xa catalytic efficiencies of C4-CY 216 were reduced 217 and 12 times respectively when albumin (10 mg ml-1) was added to the reagents, while those of CY 216 were essentially unchanged.
View Article and Find Full Text PDFEur J Epidemiol
March 1992
Centre de Transfusion Sanguine des Armées, Clamart, France.
Hepatitis A antibodies (anti-HAV) were surveyed in 1000 French recruits during 1990. The prevalence of anti-HAV in this group was 21.35%.
View Article and Find Full Text PDFJ Lab Clin Med
February 1992
Laboratoire d'hémostase, Centre de Transfusion Sanguine, Toulouse, France.
This article reports on the pharmacologic properties of an O-acylated butyryl derivative (C4-UH) of unfractionated heparin (UH). In a purified system, the ability of C4-UH to catalyze the inhibition of thrombin and of factor Xa in the presence of antithrombin III was similar to that of UH. Addition of albumin (10 mg/ml) to the reagents reduced the antithrombin and antifactor Xa catalytic potency of C4-UH 68-fold and 20-fold, respectively, and did not alter those of UH.
View Article and Find Full Text PDFBlood
January 1992
Service de Cryobiologie, Centre de Transfusion Sanguine, Lyon, France.
To evaluate the clinical value of the expression of multidrug resistance P-glycoprotein (P-170) on the surface of acute nonlymphoblastic leukemia (ANLL) cells, we analyzed specimens from 150 newly diagnosed patients for staining with MRK16, a monoclonal antibody (MoAb) that binds to an external epitope of P-170. Other surface markers (CD13, CD14, CD15, and CD34) were studied by the same technique. A marker was considered positive when 20% or more cells were stained.
View Article and Find Full Text PDF1B2 is an IgM monoclonal antibody binding to glycoconjugates bearing the terminal N-acetyllactosamine structure. It agglutinates human erythrocytes. Various cell lines, peripheral blood leucocytes, normal marrow and blast cells from 179 acute myeloid leukaemia (AML) and 11 acute lymphoblastic leukaemia (ALL) patients were tested for reactivity with 1B2.
View Article and Find Full Text PDFAm J Hematol
January 1992
Laboratoire d'immunocytologie, Centre de Transfusion Sanguine de Grenoble, La tronche, France.
Little is known about the role of tumor infiltrating T lymphocytes (TIL-T) in the pathogenesis of malignant diseases and collaboration between normal and malignant cells has not yet been proved. In the present work, we have investigated whether immune T lymphocytes exist in tumors invaded by B-cell non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). Therefore, we have studied the reactivity of the CD45RA monoclonal antibody, which discriminates between naive and memory CD4 T lymphocytes.
View Article and Find Full Text PDFNouv Rev Fr Hematol (1978)
October 1992
Laboratoire d'Hémostase, Centre de Transfusion Sanguine, Hôpital Purpan, Toulouse, France.
To determine the influence of aging on the activity of the hemostatic system, we measured the plasma concentration of prothrombin fragments 1+2 (F 1+2), thrombin-antithrombin III complexes (TAT) and fibrin degradation fragments D-dimers (D-D) in 80 healthy subjects with age ranging between 20 and 94 years. All subjects were free of acute or chronic diseases. The three markers (semi-log scale) were positively correlated with age (r greater than 0.
View Article and Find Full Text PDFBone Marrow Transplant
September 1992
Centre de Transfusion Sanguine, Annemasse, France.
Cah Anesthesiol
February 1993
Centre de Transfusion sanguine des armées Jean Julliard, Clamart.
The transfusion-sheet is an important document which appears first in the French legislation on May 1985 the 17. Its aim is to keep a close watch over transfusion of red blood cells, platelet concentrates and fresh frozen plasma and also immunohematologic evolution of data for every patient. In spite of its importance for everyone in charge of transfusion practice (physicians, biologists, transfusion center,.
View Article and Find Full Text PDFAppl Theor Electrophor
February 1993
Centre de Transfusion Sanguine CRS, Lausanne, Switzerland.
The occurrence of monoclonal gammopathy in childhood is extremely rare. This report describes the presence of a monoclonal immunoglobulin in a 30 week old premature infant, incidentally discovered by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) during an ongoing study of the plasma/serum protein development. Comparative analysis of the electrophoretogram of the infant with 'reference' protein maps revealed the presence of an 'abnormal' immunoglobulin light chain spot.
View Article and Find Full Text PDFTwo unrelated mentally retarded patients were found to have an interstitial deletion of 18q12. They were a 2-year-old, short, macrocephalic and autistic girl, and a 5-year-old boy. Six other liveborn patients with comparable deletion have been so far identified.
View Article and Find Full Text PDFBiomater Artif Cells Immobilization Biotechnol
November 1992
Centre de Transfusion Sanguine des Alpes Maritimes, St Laurent du Var, France.
New single chain neutral, and single and double chain zwitterionic perfluoroalkylated surfactants or co-surfactants have been evaluated for in vivo applications. A study of the relationship between structure and acute toxicity in mice is presented. Acute toxicity evaluations i.
View Article and Find Full Text PDFAdv Exp Med Biol
December 1992
Laboratoire d'Hémostase, Centre de Transfusion Sanguine, Toulouse, France.
Exp Clin Immunogenet
June 1993
Laboratoire d'Hémostase, Centre de transfusion sanguine, CHU Purpan, Toulouse, France.
The vitamin-D-binding protein (DBP), also called group-specific component, is well known for two main reasons: its genetic polymorphism, and its binding affinities for actin and vitamin D compounds. In recent years, additional binding affinities have been described for this puzzling molecule, without any significant biological explanations being given for these observations. The molecular genetic data for DBP are analyzed in order to show that the affinities for vitamin D are supported by the genetic variability.
View Article and Find Full Text PDFHum Mutat
May 1993
Centre de Transfusion Sanguine, CHU Mustapha, Alger, Algérie.
Thromb Res
December 1991
Laboratoire d'Hémostase, Centre de Transfusion Sanguine, Toulouse, France.
BMJ
December 1991
Centre de Transfusion Sanguine, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.